Further protection against AD-related toxicity by APPsα may arise from the inhibition of the tau phosphorylating enzyme GSK3β, thus reducing tau hyperphosphorylation and the subsequent production of NFTs (Deng et al., 2015). The gene discussed is MAPT; the disease is Alzheimer disease.